Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: Amelioration of clinical, histologic, and radiologic signs of type II collagen-induced arthritis

Arthritis and Rheumatism

Volumn 43, Issue 3, 2000, Pages 645-655

  Joosten, Leo A B ^a   Coenen de Roo, Christina J J ^b   Helsen, Monique M A ^a   Lubberts, Erik ^a   Boots, Annemieke M H ^b   Van Den Berg, Wim B ^a   Miltenburg, André M M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 39;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE ACTIVITY; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; JOINT DESTRUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES; ARTHRITIS; COLLAGEN; DOWN-REGULATION; DRUG TOLERANCE; FEMALE; GLYCOPROTEINS; HUMANS; JOINTS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA;

EID: 0034090082     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200003)43:3<645::AID-ANR22>3.0.CO;2-O     Document Type: Article

References (42)

1. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205-13.
2. Boots AMH, Verheijden GF, Schoningh R, van Staveren CJ, Bos E, Elewaut D, et al. Selection of self-reactive peptides within human aggrecan by use of an HLA-DRB1*0401 peptide binding motif. J Autoimmun 1997;10:569-78.
3. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146: 857-68.
4. Giant TT, Mikecz K, Arzoumanian A, Poole AR. Proteoglycan-induced arthritis in BALB/c mice: clinical features and histopathology. Arthritis Rheum 1987;30:201-12.
5. Verheijden GFM, Rijnders AWM, Bos E, Coenen-de Roo CJJ, van Staveren CJ, Miltenburg AMM, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997;40:1115-25.
6. Nyirkos P, Golds EE. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990;269:265-8.
7. Baeten D, DeKeyser F, Elewaut D, Rijnders AMW, Verheijden GF, Miltenburg AMM, et al. HC gp-39 expression in synovial lining is correlated with joint destruction in RA [abstract]. Arthritis Rheum 1998;41 Suppl 9:S365.
8. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10.
9. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury, analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
10. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyclitis by inhalation but not oral administration of the encephalitic peptide: influence of MHC binding affinity. Int Immunol 1993;5:1159-55.
11. Dick AD, Cheng YF, Liversidge J, Forrester JV. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis. Immunology 1994;82:625-31.
12. Daniel D, Wegman D. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide b-(9-23). Proc Natl Acad Sci USA 1996;93:956-60.
13. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-43.
14. Coenen-de Roo CJJ, Boots AMH, Verheijden GF, Bos E, Rijnders AWM, Miltenburg AMM. Human cartilage gp-39 induces and modifies a chronic relapsing arthritis in mice [abstract]. Arthritis Rheum 1998;41 Suppl 9:S214.
15. Courtenay JS, Dallman MJ, Dayan AB, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
16. Joosten LAB, Helsen MMA, van den Berg WB. Accelerated onset of collagen-induced arthritis by remote inflammation. Clin Exp Immunol 1994;97:202-11.
17. Van den Berg WB, Joosten LAB, Helsen MMA, van de Loo AAJ. Amelioration of established collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994;95:237-43.
18. Myers LK, Seyer JM, Stuart JM, Kang AH. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 1997;90:161-4.
19. Staines N, Harper N, Ward F, Bansal S. Nasal tolerance induced by collagen type II peptides prevents collagen-induced arthritis [abstract]. Arthritis Rheum 1994;37 Suppl 9:S215.
20. Johansen JS. Serum YKL-40 levels in healthy children and adults: comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35:553-9.
21. Rehli M, Krause SW, Andreesen R. Molecular characterisation of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker of late stages of macrophage differentiation. Genomics 1997;43:221-5.
22. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997;237:46-54.
23. Van den Berg WB, Joosten LAB. Murine collagen-induced arthritis. In: Morgan DW, Marshall LA, editors. In vivo models of inflammation. Basel: Birkhauser Verlag/Switzerland; 1999, p. 51-75.
24. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
25. Wolvers DAW, Coenen-de Roo CJJ, Mebius RE, van der Cammen MJF, Tirion F, Miltenburg AMM, et al. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. J Immunol 1999;162:1994-8.
26. Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40:249-60.
27. Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 1995;155:3653-9.
28. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 1998;160:3589-95.
29. Teng YT, Gorczynski RM, Hozumi N. The function of TGF-β-mediated innocent bystander suppression associated with physiological self-tolerance in vivo. Cell Immunol 1998;190:51-60.
30. Adorini L, Goldman M, Kahelitz D, Revillard J-P, Waldmann H. Apoptosis, tolerance, and immunoregulation-integrated pathways for immune system homeostasis. Immunologist 1998;6:92-4.
31. Jorgensen C, Gedon E, Jaquet C, Sany J. Gastric administration of recombinant 65kDa heat shock protein delays the severity of type II collagen induced arthritis. J Rheumatol 1998;25:763-7.
32. Prakken BJ, van der Zee R, Anderton SM, van Kooten PJS, Kuis W, van Eden W. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrohially induced experimental arthritis. Proc Natl Acad Sci U S A 1997;94:3284-9.
33. Morgan K, Clague RB, Shaw MJ, Firth SA, Twosc TM, Holt PJL. Native type II collagen-induced arthritis in the rat: the effect of complement depletion by cobra venom factor. Arthritis Rheum 1981;24:1356-62.
34. Heath WR, Kurts C, Miller JFAP, Carbone F. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998;187:1549-53.
35. Wraith DC. Antigen-specific immunotherapy of autoimmune disease: a commentary. Clin Exp Immunol 1996;103:349-52.
36. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997;40:2105-15.
37. Jacobs MJM, van den Hock AEM, van de Putte LBA, van den Berg WB. Anergy of antigen-specific T-lymphocytes is a potent mechanism of intravenously induced tolerance. Immunology 1994; 82:294-300.
38. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994;264:1587-9.
39. Tanaka T, Hu-Li J, Seder RA, Fazekas-de-St.-Groth B, Paul WE. Interleukin 4 suppresses interleukin-2 and Interferon gamma production by naive T cell stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci U S A 1993;90:5914-8.
40. Snowden N, Reynolds I, Morgan K, Holt L. T cell responses to human type II collagen in patients with rheumatoid arthritis and healthy controls. Arthritis Rheum 1997;40:1210-8.
41. Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, et al. Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996;39:41-51.
42. Barnett ML, Kremer JM, St. Clair EW, Clegg DO, Furst D, Weisman W, et al. Treatment of rheumatoid arthritis with oral type II collagen: results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998;41:290-7.